Literature DB >> 9153583

Serpins inhibit the toxicity of amyloid peptides.

D Schubert1.   

Abstract

The amyloid plaque in Alzheimer's disease (AD) contains numerous proteins, some of which may be relevant to the pathogenesis of the disease. The serine protease inhibitor alpha1-antichymotrypsin is specifically localized in AD plaques. It is shown here that alpha1-antichymotrypsin and several other serine protease inhibitors (serpins) inhibit the toxicity of amyloid peptides on primary cortical nerve cell cultures as well as a clonal cell line. This inhibition of toxicity is not mediated via the serpin enzyme complex receptor, the transferrin receptor, or by interference with the polymerization of amyloid fibrils. Since a variety of synthetic serine protease inhibitors mimic the effects of serpins on amyloid toxicity, it is likely that the antiprotease activities of serpins are responsible for their biological effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153583     DOI: 10.1111/j.1460-9568.1997.tb01425.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  6 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice.

Authors:  L Mucke; G Q Yu; L McConlogue; E M Rockenstein; C R Abraham; E Masliah
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain.

Authors:  S A Frautschy; D L Horn; J J Sigel; M E Harris-White; J J Mendoza; F Yang; T C Saido; G M Cole
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

4.  Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers.

Authors:  Jiaxin Yu; Lara Bakhos; Lei Chang; Mark J Holterman; William L Klein; Duane L Venton
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

5.  Sex-specific genetic predictors of Alzheimer's disease biomarkers.

Authors:  Yuetiva Deming; Logan Dumitrescu; Lisa L Barnes; Madhav Thambisetty; Brian Kunkle; Katherine A Gifford; William S Bush; Lori B Chibnik; Shubhabrata Mukherjee; Philip L De Jager; Walter Kukull; Matt Huentelman; Paul K Crane; Susan M Resnick; C Dirk Keene; Thomas J Montine; Gerard D Schellenberg; Jonathan L Haines; Henrik Zetterberg; Kaj Blennow; Eric B Larson; Sterling C Johnson; Marilyn Albert; Abhay Moghekar; Jorge L Del Aguila; Maria Victoria Fernandez; John Budde; Jason Hassenstab; Anne M Fagan; Matthias Riemenschneider; Ronald C Petersen; Lennart Minthon; Michael J Chao; Vivianna M Van Deerlin; Virginia M-Y Lee; Leslie M Shaw; John Q Trojanowski; Elaine R Peskind; Gail Li; Lea K Davis; Julia M Sealock; Nancy J Cox; Alison M Goate; David A Bennett; Julie A Schneider; Angela L Jefferson; Carlos Cruchaga; Timothy J Hohman
Journal:  Acta Neuropathol       Date:  2018-07-02       Impact factor: 17.088

6.  Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review.

Authors:  David Vogrinc; Katja Goričar; Vita Dolžan
Journal:  Front Aging Neurosci       Date:  2021-03-18       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.